These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29859482)

  • 1. Which type of breast cancers is undetectable on ring-type dedicated breast PET?
    Sasada S; Masumoto N; Goda N; Kajitani K; Emi A; Kadoya T; Okada M
    Clin Imaging; 2018; 51():186-191. PubMed ID: 29859482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of radioactivity outside the field of view on image quality of dedicated breast positron emission tomography: preliminary phantom and clinical studies.
    Satoh Y; Imai M; Ikegawa C; Hirata K; Abo N; Kusuzaki M; Oyama-Manabe N; Onishi H
    Ann Nucl Med; 2022 Dec; 36(12):1010-1018. PubMed ID: 36207497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral heterogeneity on dedicated breast positron emission tomography predicts malignancy grade of breast cancer.
    Masumoto N; Kadoya T; Sasada S; Emi A; Arihiro K; Okada M
    Breast Cancer Res Treat; 2018 Sep; 171(2):315-323. PubMed ID: 29779072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer.
    Sasada S; Shiroma N; Goda N; Kajitani K; Emi A; Masumoto N; Kadoya T; Arihiro K; Okada M
    Breast Cancer Res Treat; 2019 Oct; 177(3):651-657. PubMed ID: 31267329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher breast cancer conspicuity on dbPET compared to WB-PET/CT.
    Nishimatsu K; Nakamoto Y; Miyake KK; Ishimori T; Kanao S; Toi M; Togashi K
    Eur J Radiol; 2017 May; 90():138-145. PubMed ID: 28583624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dedicated breast PET for detecting residual disease after neoadjuvant chemotherapy in operable breast cancer: A prospective cohort study.
    Sasada S; Masumoto N; Goda N; Kajitani K; Emi A; Kadoya T; Okada M
    Eur J Surg Oncol; 2018 Apr; 44(4):444-448. PubMed ID: 29396328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of dedicated breast positron emission tomography.
    Hashimoto R; Akashi-Tanaka S; Watanabe C; Masuda H; Taruno K; Takamaru T; Ide Y; Kuwayama T; Kobayashi Y; Takimoto M; Nakamura S
    Breast Cancer; 2022 Nov; 29(6):1013-1021. PubMed ID: 35768684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of dedicated breast positron emission tomography and whole-body positron emission tomography/computed tomography images: a common phantom study.
    Satoh Y; Motosugi U; Imai M; Onishi H
    Ann Nucl Med; 2020 Feb; 34(2):119-127. PubMed ID: 31768819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer detection by dedicated breast positron emission tomography according to the World Health Organization classification of breast tumors.
    Sasada S; Kimura Y; Masumoto N; Emi A; Kadoya T; Arihiro K; Okada M
    Eur J Surg Oncol; 2021 Jul; 47(7):1588-1592. PubMed ID: 33685728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unexpected Abnormal Uptake in the Breasts at Dedicated Breast PET: Incidentally Detected Small Cancers or Nonmalignant Features?
    Satoh Y; Motosugi U; Omiya Y; Onishi H
    AJR Am J Roentgenol; 2019 Feb; 212(2):443-449. PubMed ID: 30476450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dedicated breast PET value to evaluate BI-RADS 4 breast lesions.
    Graña-López L; Herranz M; Domínguez-Prado I; Argibay S; Villares A; Ruibal A; Vázquez-Caruncho M
    Eur J Radiol; 2018 Nov; 108():201-207. PubMed ID: 30396656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
    Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
    Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance evaluation of a high resolution dedicated breast PET scanner.
    García Hernández T; Vicedo González A; Ferrer Rebolleda J; Sánchez Jurado R; Roselló Ferrando J; Brualla González L; Granero Cabañero D; Del Puig Cozar Santiago M
    Med Phys; 2016 May; 43(5):2261. PubMed ID: 27147338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution pattern of FDG uptake using ring-type dedicated breast PET in comparison to whole-body PET/CT scanning in invasive breast cancer.
    Sakaguchi R; Kataoka M; Kanao S; Miyake KK; Nakamoto Y; Sugie T; Toi M; Mikami Y; Togashi K
    Ann Nucl Med; 2019 Aug; 33(8):570-578. PubMed ID: 31115856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous whole-body and breast 18F-FDG PET/MRI examinations in patients with breast cancer: a comparison of apparent diffusion coefficients and maximum standardized uptake values.
    Sasaki M; Tozaki M; Kubota K; Murakami W; Yotsumoto D; Sagara Y; Ohi Y; Oosako S; Sagara Y
    Jpn J Radiol; 2018 Feb; 36(2):122-133. PubMed ID: 29159779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classification of Abnormal Findings on Ring-type Dedicated Breast PET for the Detection of Breast Cancer.
    Sasada S; Masumoto N; Kimura Y; Emi A; Kadoya T; Okada M
    Anticancer Res; 2020 Jun; 40(6):3491-3497. PubMed ID: 32487649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
    Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
    Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The feasibility of dedicated breast PET for the assessment of residual tumor after neoadjuvant chemotherapy.
    Koyasu H; Goshima S; Noda Y; Nishibori H; Takeuchi M; Matsunaga K; Yamada T; Matsuo M
    Jpn J Radiol; 2019 Jan; 37(1):81-87. PubMed ID: 30392134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First clinical experience with a dedicated PET for hanging breast molecular imaging.
    Koolen BB; Aukema TS; González Martínez AJ; Vogel WV; Caballero Ontanaya L; Vrancken Peeters MJ; Vroonland CJ; Rutgers EJ; Benlloch Baviera JM; Valdés Olmos RA
    Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):92-100. PubMed ID: 23474637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor metabolism and perfusion ratio assessed by 18F-FDG PET/CT and DCE-MRI in breast cancer patients: Correlation with tumor subtype and histologic prognostic factors.
    An YS; Kang DK; Jung YS; Han S; Kim TH
    Eur J Radiol; 2015 Jul; 84(7):1365-70. PubMed ID: 25886700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.